JHVEPhoto/iStock Editorial via Getty Images
- Abeona Therapeutics (NASDAQ:ABEO) announced that the FDA has accepted for review Abeona’s resubmission of its Biologics License Application for prademagene zamikeracel, its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa.
- The FDA has assigned a Prescription Drug User Fee Act target action date of April 29, 2025.
- Source: Press Release